BrightSpring Health Services, Inc. Tangible Equity Unit · BTSGU · FY2026 Q1 · Calendar Q2 2026
BrightSpring posts strong Q1 growth and reaffirms 2026 guidance
The quarter supports a constructive operating trajectory: strong revenue and EBITDA growth, lower leverage and continued infusion and LDD expansion provide evidence of resilient demand and capacity to invest. The case remains dependent on integration execution, regulatory headwinds and disciplined leverage management.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about BTSGU FY2026 Q1
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
BrightSpring completed the Community Living divestiture, generating $811 million of net cash proceeds and reducing leverage to 2.27x. Management also highlighted expected first-year EBITDA from Amedisys and LHC assets and expanded AI automation efforts, while maintaining full-year guidance.
Guidance delta
Management reaffirmed 2026 revenue guidance of $14.7-$15.2 billion and adjusted EBITDA guidance of $795-$825 million; no change was indicated.
Key takeaways
- Revenue grew 26% year over year to $3.6 billion, with Pharmacy Solutions up 25% and Provider Services up 28%.
- Adjusted EBITDA margin improved 70 basis points to 5.3%, while leverage declined to 2.27x after the Community Living sale.
- Infusion delivered double-digit growth, the LDD portfolio reached 153 products, and 2026 guidance was reaffirmed.
Management priorities
- Expand chronic infusion coverage and launch concierge programs for IVIG and targeted therapies.
- Pursue LDD acquisitions and exclusive contracts while expanding value-based care.
- Integrate Amedisys and LHC assets and develop AI-driven operational automation.
Follow BTSGU with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Company context
Snapshot as of publicationBrightSpring Health Services, Inc. is a U.S.-based healthcare organization that provides a comprehensive suite of services directly to individuals in their homes and local communities. The company's primary focus is on delivering pharmacy and direct patient care services, encompassing both clinical treatment and supportive assistance. These services are specifically tailored for populations covered by Medicare, Medicaid, and private insurance. Care is administered by a network of clinical providers and pharmacists. Established in 1974, the firm is headquartered in Louisville, Kentucky, and adopted its current name, BrightSpring Health Services, Inc., in May 2021, having previously been known as Phoenix Parent Holdings Inc.
Historical context
All BTSGU earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| AZN AstraZeneca PLC | FY2026 Q3 · Calendar Q4 2026 | +7.3% | +7.0% | AstraZeneca pairs solid growth with pipeline investment and restructuring |
| BTSG BrightSpring Health Services, Inc. Common Stock | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +11.1% | BrightSpring posts strong Q3 growth while maintaining guidance |
| ABBV AbbVie Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.4% | +1.4% | AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive Q3 growth |
| REGN Regeneron Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | +21.6% | +13.3% | Regeneron posts strong Q3 growth as pipeline expands |
| EXEL Exelixis, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.0% | +4.8% | Exelixis highlights zanzalintinib pipeline after strong Q3 |
| BBIO BridgeBio Pharma, Inc. | FY2026 Q3 · Calendar Q4 2026 | +22.5% | +6.0% | BridgeBio advances three launches while Attruby momentum holds |
Latest beats and misses
Who reports nextBeat on EPS
- CHDFY2026 Q3 · October 30, 2026+2.2% EPS+1.2% move
- AZNFY2026 Q3 · October 30, 2026+7.3% EPS+7.0% move
- FRTFY2026 Q3 · October 30, 2026+3.9% EPS-1.1% move
- CVXFY2026 Q3 · October 30, 2026+8.4% EPS+1.8% move
- BTSGFY2026 Q3 · October 30, 2026+14.2% EPS+11.1% move
- EXCFY2026 Q3 · October 30, 2026+10.4% EPS+0.5% move
Missed on EPS
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- DLR-PLFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLR-PKFY2026 Q3 · October 29, 2026-8.4% EPS— move
Get the BTSGU recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-11-01T17:10:42.522900+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-01. For educational purposes only; not investment advice.